Peter B. Bach on Muck Rack

Peter B. Bach

New York
As seen in: The New York Times, Bloomberg News, Bloomberg Opinion, Color Research & Application, The Wall Street Journal, Yahoo Finance, Fortune, Harvard Business Review, MDPI, New York Magazine and
Chief Med Officer @DELFIdiagnostic. Pulmonary & ICU doc. Tweets about health policy and grammar. Viewpoints my own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Peter B.

Contact Peter B., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Innovations in Early Lung Cancer Detection: Tracing the Evolution and Advancements in Screening

|
By Peter B. Bach, Caitlin A. Schonewolf, Lindsey B. Cotton, Chris Cisar
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Bach, Redberg: Medicare needs to test the new Alzheimer’s drug before paying

|
By Peter B. Bach, Rita F. Redberg
| Pioneer Press
Since last summer, Medicare has been evaluating whether to pay for a newly approved, exorbitantly priced drug to treat Alzheimer’s disease. Its decision was always going to be fraught: The data on the drug’s potential benefits are ambiguous at best, and its risks are considerable. About 40% of patients who have taken it have suffered swelling or bleeding in the brain. Others have experienced disabling nausea, dizziness, headaches and confusion.
Open in Who Shared View Duplicates (7) Issue with article?

National Opinion: Medicare needs to test the new Alzheimer’s drug before paying

|
By Peter B. Bach
| Arizona Daily Star
The following column is the opinion and analysis of the writer: Since last summer, Medicare has been evaluating whether to pay for a newly approved, exorbitantly priced drug to treat Alzheimer’s disease. Its decision was always going to be fraught: The data on the drug’s potential benefits are ambiguous at best, and its risks are considerable. About 40% of patients who have taken it have suffered swelling or bleeding in the brain.
Open in Who Shared View Duplicates (3) Issue with article?
See all 82 licensed articles (106 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Peter B.

Contact Peter B., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified